ArticleJournal of gastrointestinal cancer2024

Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.

Florinda A Santos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.